1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine - Pharmacology
Research News and Information

Sunday, November 22, 2009

Sirtuin 1 overexpression mice show a reference memory deficit, but not neuroprotection.

26 Jul 2009 Sirtuin 1 (SIRT1) is the closest mammalian homologue of yeast silent information regulator 2 (Sir2) and has a role in lifespan modulation. Reportedly, SIRT1 is also linked to neurodegenerative diseases. However, there are limited studies that report ... Read more...

Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model.

23 Jul 2009 To replicate the sleep-wake disorders of Parkinson's disease (PD) and to understand the temporal relationship between these sleep disturbances and the occurrence of parkinsonism, we performed long-term continuous electroencephalographic monitoring ... Read more...

Activation of phosphatidylinositol-linked D1-like receptor modulates FGF-2 expression in astrocytes via IP3-dependent Ca2+ signaling.

15 Jun 2009 Fibroblast growth factor-2 (FGF-2) is predominantly synthesized and secreted by astrocytes in adult brain. Our previous study showed that activation of classical dopamine receptor D(1) or D(2) elicits FGF-2 biosynthesis and secretion in astrocytes. ... Read more...

Latest indexed articles for '1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine - Pharmacology'

These are the very latest articles for this heading:

• Sirtuin 1 overexpression mice show a reference memory deficit, but not neuroprotection. 26 Jul 2009
• Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model. 23 Jul 2009
• Activation of phosphatidylinositol-linked D1-like receptor modulates FGF-2 expression in astrocytes via IP3-dependent Ca2+ signaling. 15 Jun 2009
• Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum. 7 Jun 2009
• Two new test methods to quantify motor deficits in a marmoset model for Parkinson's disease. 6 Jun 2009
• Not lost in translation Sensing the loss and filling the gap during regeneration. 18 May 2009
• Activation of p38 MAPK in the substantia nigra leads to nuclear translocation of NF-kappaB in MPTP-treated mice: implication in Parkinson's disease. 9 May 2009
• Strain-specific sensitivity to MPTP of C57BL/6 and BALB/c mice is age dependent. 4 May 2009
• In vitro dopaminergic neuroprotective and in vivo antiparkinsonian-like effects of Delta 3,2-hydroxybakuchiol isolated from Psoralea corylifolia (L.). 29 Apr 2009
• Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP. 27 Apr 2009
• Systemic administration of proteasome inhibitor protects against MPTP neurotoxicity in mice. 14 Apr 2009
• Blockade of PrRP attenuates MPTP-induced toxicity in mice. 24 Mar 2009
• Decreased inflammation and augmented expression of trophic factors correlate with MOG-induced neuroprotection of the injured nigrostriatal system in the murine MPTP model of Parkinson's disease. 11 Mar 2009
• Effect of a prolyl endopeptidase inhibitor benzyloxycarbonyl-alanyl-proline on the development of experimental depressive syndrome in rats. 27 Feb 2009
• Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. 3 Feb 2009
• Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopaminergic neuronal damage in mouse model of Parkinson's disease. 27 Jan 2009
• Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration. 18 Jan 2009
• [No-dependent modulation of the sensitivity of the mitochondrial permeability transition pore opening under ischemia-reperfusion of the isolated heart] 30 Dec 2008
• 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) does not elicit long-lasting increases in cyclooxygenase-2 expression in dopaminergic neurons of monkeys. 30 Dec 2008
• Modulation of neurotoxicant-induced increases in intracellular calcium by phytoestrogens differ for amyloid beta peptide (Abeta) and 1-methyl-4-phenyl-pyridine (MPP(+)). 30 Dec 2008

See a longer list of these articles.

Technical information about '1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine'

Definition: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.

Chemical name: Pyridine, 1,2,3,6-tetrahydro-1-methyl-4-phenyl-

Registry Number: 28289-54-5

Descriptor UI: D015632

Alternative terms: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MPTP;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; radiation effects; standards; supply & distribution; therapeutic use; urine; chemistry; contraindications; agonists;

Pharmacological Action: Dopamine Agents; Neurotoxins;

Tree Number: D03.383.725.450;

History Note: 90